DNA vaccine shows promise against anal precancer in HIV patients

NCT ID NCT03603808

First seen May 02, 2026 · Last updated May 14, 2026 · Updated 3 times

Summary

This study tested a DNA-based vaccine called VGX-3100 in 44 HIV-positive adults with high-grade anal precancer caused by HPV types 16 or 18. The vaccine was given with a mild electrical pulse (electroporation) to help cells absorb it and boost the immune response. The goal was to see if the treatment could shrink or eliminate the precancerous lesions. The study was completed and measured how many participants had their lesions regress to low-grade or normal tissue after 48 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAL INTRAEPITHELIAL NEOPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Anal Dysplasia Clinic MidWest

    Chicago, Illinois, 60614, United States

  • Boston Medical Center

    Boston, Massachusetts, 02118, United States

  • Grady Health System

    Atlanta, Georgia, 30303, United States

  • Laser Surgery Care

    New York, New York, 10011, United States

  • Montefiore Medical Center

    The Bronx, New York, 10461, United States

  • University of California, San Francisco

    San Francisco, California, 94143, United States

  • University of Puerto Rico

    San Juan, 00936-3027, Puerto Rico

  • Wake Forest Baptist health Sciences

    Winston-Salem, North Carolina, 27157, United States

Conditions

Explore the condition pages connected to this study.